To explore this, we rationally designed and synthesized a tumor-selective prodrug, H62, by conjugating our potent DHODH inhibitor EA6 with the validated STING agonist MSA-2 (MSA) via a cathepsin B (CTSB)-cleavable linker. The gene discussed is CTSB; the disease is neoplasm.